Myositisspezifische Antikörper bei juveniler Dermatomyositis

Betteridge ZE, Gunawardena H, McHugh NJ (2011) Novel autoantibodies and clinical phenotypes in adult and juvenile myositis. Arthritis Res Ther 13:209

Bohan A, Peter JB (1975) Polymyositis and dermatomyositis (first of two parts). N Engl J Med 292:344–347

Brown VE et al (2006) An international consensus survey of the diagnostic criteria for juvenile dermatomyositis (JDM). Rheumatology (Oxford) 45:990–993

Feldman BM, Reichlin M, Laxer RM, Targoff IN, Stein LD, Silverman ED (1996) Clinical significance of specific autoantibodies in juvenile dermatomyositis. J Rheumatol 23:1794–1797

Feldmann BM, Rider LG, Reed AM, Pachmann LM (2008) Juvenile dermatomyositis and other idiopathic inflammatory myopathies of childhood. Lancet 371:2201–2212

Gunawardena H, Betteridge Z, McHugh NJ (2009) Myositis-specific autoantibodies: their clinical and pathogenic significance in desease expression. Rheumatology (Oxford) 48:607–612

Gunawardena H, Wedderburn LR, Chinoy H et al (2009) Juvenile Dermatomyositis Research Group, UK and Ireland: autoantibodies to a 140-kd protein in juvenile dermatomyositis are associated with calcinosis. Arthritis Rheum 60:1807–1814

Gunarwardena H, Wedderburn LR, North J, Betteridge Z, Dunphy J, Chinoy H et al (2008) Clinical associations of autoantibodies to a p155/140 kDa doublet protein in juvenile dermatomyositis. Rheumatology (Oxford) 47:324–328

Kimura Y, Sakai F, Nakano O et al (2002) The newly identified human nuclear protein NXP-2 possesses three distinct domains, the nuclear matrix-binding, RNA-binding and coiled-coil domains. J Biol Chem 277:20611–20617

Kobayashi N, Takezaki S, Kobayashi I, Iwata N, Mori M, Nagai K, Nakano N, Miyoshi M, Kinjo N, Murata T, Masunaga K, Umebayashi H, Imagawa T, Agematsu K, Sato S, Kuwana M, Yamada M, Takei S, Yokota S, Koike K, Ariga T (2015) Clinical and laboratory features of fatal rapidly progressive interstitial lung disease associated with juvenile dermatomyositis. Rheumatology (Oxford) 54(5):784–791

Love LA, Leff RL, Fraser DD et al (1991) A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups. Medicine (Baltimore) 70:360–374

Lundberg IE et al (2017) 2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. Arthritis Rheumatol. https://doi.org/10.1002/art.40320

Mammen AL (2011) Autoimmune myopathies: autoantibodies, phenotypes and pathogenesis. Nat Rev Neurol 7:343–354

Mendez EP et al (2003) US incidence of juvenile dermatomyositis, 1995–1998: results from the National Institute of Arthritis and Musculoskeletal and Skin Diseases Registry. Arthritis Rheum 49:300–305

Morris P, Dare J (2010) Juvenile dermatomyositis as a paraneoplastic phenomenon: an update. J Pediatr Hematol Oncol 32:189–191

Oberle EJ, Bayer ML, Chiu YE, Co DO (2017) How often are pediatric patients with clinically amyopathic dermatomyositis truly amyopathic? Pediatr Dermatol 34:50–57

Reeves WH, Nigam SK, Blobel G (1986) Human autoantibodies reactive with signal-recognition particle. Proc Natl Acad Sci Usa 83:9507–9570

Rider LG, Miller FW, Targoff IN, Sherry DD, Samayoa E, Lindahl M, Wener MH, Pachman LM, Plotz PH (1994) A broadened spectrum of juvenile myositis. Myositis-specific autoantibodies in children. Arthritis Rheum 37:1534–1538

Rider LG, Nistala K (2016) The juvenile idiopathic inflammatory myopathies: pathogenesis, clinical and autoantibody phenotypes, and outcomes. J Intern Med 280:24–38

Rider LG, Shah M, Mamyrova G, Huber AM, Rice MM, Targoff IN, Miller FW (2013) Childhood Myositis Heterogeneity Collaborative Study Group. The myositis autoantibody phenotypes of the juvenile idiopathic inflammatory myopathies. Medicine (Baltimore) 92:223–243

Shah M, Mamyrova G, Targoff IN et al (2013) The clinical phenotypes of the juvenile idiopathic inflammatory myopathies. Medicine (Baltimore) 92:25–41

Symmons DP, Sills JA, Davis SM (1995) The incidence of juvenile dermatomyositis: results from a nation-wide study. Br J Rheumatol 34:732–736

Tansley S, Betteridge Z, Gunawardena H et al (2012) Clinical differences between adult and juvenile dermatomyositis associated with anti-NXP2 autoantibodies. ACR, Atlanta (abstract)

Tansley SL, McHugh NJ (2014) Myositis specific and associated autoantibodies in the diagnosis and management of juvenile and adult idiopathic inflammatory myopathies. Curr Rheumatol Rep 16:464

Targoff IN, Trieu EP, Levy-Neto M, Fertig N, Oddis CV (2007) Sera with autoantibodies to the MJ antigen react with NXP2. Arthritis Rheum 56:787

Wang HB, Zhang Y (2001) Mi2, an auto-antigen for dermatomyositis, is an ATP-dependent nucleosome remodeling factor. Nucleic Acids Res 29:2517–2521

Wedderburn LR, McHugh NJ, Chinoy H, Cooper RG, Salway F, Ollier WE, McCann LJ, Varsani H, Dunphy J, North J, Davidson JE Juvenile Dermatomyositis Research Group (JDRG) (2007) HLA class II haplotype and autoantibody associations in children with juvenile dermatomyositis and juvenile dermatomyositis-scleroderma overlap. Rheumatology (Oxford) 46:1786–1791